Revisiting the prehypertension debate: Increasing evidence for treatment yet randomized clinical trials are lacking

References

• Kiely AE, Kwatra SG, Kwatra MM. Treating prehypertension: Medically sound and economically viable. Blood Press. 2009;18:300–303.
   PubMed Web of Science ®Google Scholar
• McInnes GT. Drug treatment of prehypertension: Not now, not ever?Blood Press. 2009;18:304–307.
   PubMed Web of Science ®Google Scholar
• Lee M, Saver JL, Chang B, Chang KH, Hao Q, Ovbiagele B. Presence of baseline prehypertension and risk of incident stroke: A meta-analysis. Neurology. 2011;77: 1330–1337.
   PubMed Web of Science ®Google Scholar
• Ninomiya T, Ohara T, Hirakawa Y, Yoshida D, Doi Y, Hata J, et al. Midlife and late-life blood pressure and dementia in Japanese elderly: The Hisayama study. Hypertension. 2011; 58:22–28.
   PubMed Web of Science ®Google Scholar
• Launer LJ, Hughes T, Yu B, Masaki K, Petrovitch H, Ross GW, et al. Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: Perspective from the Honolulu Heart Program/Honolulu Asia Aging Study. Hypertension. 2010;55:1352–1359.
   PubMed Web of Science ®Google Scholar
• Qiu C, Hu G, Kivipelto M, Laatikainen T, Antikainen R, Fratiglioni L, et al. Association of blood pressure and hypertension with the risk of Parkinson disease: The National FINRISK Study. Hypertension. 2011;57:1094–1100.
   PubMed Web of Science ®Google Scholar
• Hsu CC, Brancati FL, Astor BC, Kao WH, Steffes MW, Folsom AR, et al. Blood pressure, atherosclerosis, and albuminuria in 10,113 participants in the atherosclerosis risk in communities study. J Hypertens. 2009;27:397–409.
   PubMed Web of Science ®Google Scholar
• Crews DC, Plantinga LC, Miller ER, 3rd, Saran R, Hedgeman E, Saydah SH, et al. Prevalence of chronic kidney disease in persons with undiagnosed or prehypertension in the United States. Hypertension. 2010;55:1102–1109.
   PubMed Web of Science ®Google Scholar
• Yano Y, Fujimoto S, Sato Y, Konta T, Iseki K, Moriyama T, et al. Association between prehypertension and chronic kidney disease in the Japanese general population. Kidney Int. 2012; 81:293–299.
   PubMed Web of Science ®Google Scholar
• Mullican DR, Lorenzo C, Haffner SM. Is prehypertension a risk factor for the development of type 2 diabetes?Diabetes Care. 2009;32:1870–1872.
   PubMedGoogle Scholar
• Kramer CK, von Muhlen D, Barrett-Connor E. Mid-life blood pressure levels and the 8-year incidence of type 2 diabetes mellitus: The Rancho Bernardo Study. J Hum Hypertens. 2010;24:519–524.
   PubMedGoogle Scholar
• Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation. 2003;107: 2920–2925.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, et al. Outcome parameters for trials in atrial fibrillation: Executive summary. Eur Heart J. 2007;28:2803–2817.
   PubMed Web of Science ®Google Scholar
• Ringborg A, Nieuwlaat R, Lindgren P, Jonsson B, Fidan D, Maggioni AP, et al. Costs of atrial fibrillation in five European countries: Results from the Euro Heart Survey on atrial fibrillation. Europace. 2008;10:403–411.
   PubMed Web of Science ®Google Scholar
• Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota,1980 to 2000, and implications on the projections for future prevalence.Circulation.2006;114:119–125.
   Google Scholar
• Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98:476–484.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Am J Cardiol. 1998; 82:2N–9N.
   PubMed Web of Science ®Google Scholar
• Tveit A, Grundvold I, Olufsen M, Seljeflot I, Abdelnoor M, Arnesen H, et al. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol. 2007;120:85–91.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12:1360–1420.
   PubMed Web of Science ®Google Scholar
• Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, Bergmann A, et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol. 2010;56:1712–1719.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A, et al. Prevention of atrial fibrillation: Report from a national heart, lung, and blood institute workshop. Circulation. 2009;119:606–618.
   PubMed Web of Science ®Google Scholar
• Grundvold I, Skretteberg PT, Liestol K, Erikssen G, Kjeldsen SE, Arnesen H, et al. Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: A 35-year follow-up study. Hypertension. 2012;59:198–204.
   PubMed Web of Science ®Google Scholar
• Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation. 2009;119:2146–2152.
   PubMed Web of Science ®Google Scholar
• Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354: 1685–1697.
   PubMed Web of Science ®Google Scholar
• Luders S, Schrader J, Berger J, Unger T, Zidek W, Bohm M, et al. The PHARAO study: Prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: A prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26:1487–1496.
   PubMed Web of Science ®Google Scholar
• Kwatra SG, Kiely AE, Kwatra MM. Prehypertension: To treat or not to treat should no longer be the question. Hypertension. 2012;59: e27; author reply e8.
   PubMedGoogle Scholar
• Sipahi I, Swaminathan A, Natesan V, Debanne SM, Simon DI, Fang JC. Effect of antihypertensive therapy on incident stroke in cohorts with prehypertensive blood pressure levels: A meta-analysis of randomized controlled trials. Stroke. 2012; 43:432–440.
   PubMedGoogle Scholar
• Fuchs FD, Fuchs SC, Moreira LB, Gus M, Nobrega AC, Poli-de-Figueiredo CE, et al. Prevention of hypertension in patients with pre-hypertension: Protocol for the PREVER-prevention trial. Trials. 2011;12:65.
   PubMedGoogle Scholar